Decision-making strategy in cardiac surgical patient with flare up of gout under ticagrelor use
AbstractPractitioners should take into account the high risk of early cardiovascular events after coronavirus infection in operated patients with coronary heart disease and the presence of concomitant diseases when prescribing antiplatelet drugs. The article presents a clinical case of the gout flash during the ticagrelor application in patient after stenting with a demonstration of ability to save adherence to the antiplatelet agent after short-term analgesic therapy.
Keywords:acute coronary syndrome; ticagrelor; COVID 19; gout; adherence
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
For citation: Sizova L.V., Averyanov V.N. Decision-making strategy in cardiac surgical patient with flare up of gout under ticagrelor use. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2022; 10 (3): 59–62. DOI: https://doi.org/10.33029/2309-1908-2022-10-3-59-62 (in Russian)
References
1. Puntmann V.O., Careri M.L., Wieters I., et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5 (11): 1265–73. DOI: https://doi.org/10.1001/jamacardio.2020.3557
2. Case B.C., Yerasi Ch., Forrestal B.J., et al. The impact of COVID-19 patients with troponin elevation on renal impairment and clinical outcome. Cardiovasc Revasc Med. 2021; 33: 45–84. DOI: https://doi.org/10.1016/j.carrev.2021.05.004
3. Obrezan A.A., Solov’eva M.V., Mikhaylova L.V., Zaytsev V.V., Kon’ V.E., Panov A.V. Comorbidity in patients with cardiovascular disease who underwent a new coronavirus infection. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2022; 10 (2): 51–6. DOI: https://doi.org/10.33029/2309-1908-2022-10-2-51-56 (in Russian)
4. Adu-Amankwaah J., Mprah R., Adekunle A.O., et al. The cardiovascular aspect of COVID-19. Ann Med. 2021; 53 (1): 227–36. DOI: https://doi.org/10.1080/07853890.2020.1861644
5. Augustine R., Abhilash S. Nayeem A., et al. Increased complications of COVID-19 in people with cardiovascular disease: role of the renin-angiotensin-aldosterone system (RAAS) dysregulation. Chem Biol Interact. 2022; 351 (5): 109738. DOI: https://doi.org/10.1016/j.cbi.2021.109738
6. Drapkina O.M., Vasil’eva L.E. Debatable points of using angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists in patients with COVID-19. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2020; 19 (3): 2580. DOI: https://doi.org/10.15829/1728-8800-2020-2580 (in Russian)
7. Dobesh P.P., Oestreich J.H. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy. 2014; 34 (10): 1077–90. DOI: https://doi.org/10.1002/phar.1477
8. Jourdi G., Marquis-Gravel G., Martin A.C., et al. Antiplatelet therapy in atherothrombotic diseases: similarities and differences across guidelines. Front Pharmacol. 2022; 13: 878416. DOI: https://doi.org/10.3389/fphar.2022.878416
9. Linder M., Andersen M. Patient characteristics and safety outcomes in new users of ticagrelor and clopidogrel – an observational cohort study in Sweden. Pharmacoepidemiol Drug Saf. 2022; 31 (2): 235–46. DOI: https://doi.org/10.1002/pds.5387
10. Zhang N., Zhang Z., Yang Y., et al. Ticagrelor-related gout: an underestimated side effect. Int. J Cardiol. 2015; 192: 11–3. DOI: https://doi.org/10.1016/j.ijcard.2015.05.023